AfterRaise/Companies/Basecamp Research

Basecamp Research

Basecamp Research is a provider of an AI platform for therapeutic design. From its funding announcement.

$140M Series CRaised yesterdayLondon, UKBiotech & PharmaUK
Visit website →

In their own words

What Basecamp Research says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "provider of an AI platform for therapeutic design". Source

Market expansionProduct

Public signal Read from the company's own description of what the funding supports.

Why now

Where Basecamp Research is today

Basecamp Research announced a Series C round of $140M on 23 September 2026, led by S32.

Latest round
Series C
Amount
$140M
Announced
23 September 2026
Headquarters
London, UK
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Also participating
Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, Rockefeller Foundation, Singular, Sovereign AI, True
Relevant leadership
CEO Glen Gowers

Momentum AfterRaise intelligence

AfterRaise Score

82
High momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
22/25
round size relative to the market
Funding stage
20/20
Series C
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 23 September 2026
    $140M Series C
    Led by S32.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Product launches and new tiers

Opportunities this could create

  • Licensing and BD partnerships
  • Market-entry advisers
  • Local employment infrastructure
  • In-market partnerships
  • Product leadership

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 23 September 2026$140M Series C announced
  • 23 September 2026Stated priority: market expansion
  • 23 September 2026Stated priority: product

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Basecamp Research is open to

Not yet specified

Basecamp Research has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Basecamp Research

All opportunities

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Basecamp Research?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector